MYGN Director Bisaro Paul Buys 7,500 Shares on May 14, 2026

When insiders buy stock with their own money, Wall Street pays attention. It’s a powerful signal that company leaders believe in the business. Today we’re examining a significant insider purchase at Myriad Genetics, Inc. Director Bisaro Paul acquired 7,500 shares of MYGN on May 14, 2026, investing approximately $27,637.50 at $3.69 per share. This insider transaction reveals confidence in the genomics company’s direction and provides investors with real data about executive sentiment.

Insider Purchase Details and Transaction Breakdown

Director Bisaro Paul’s purchase represents a meaningful commitment to Myriad Genetics. The transaction occurred on May 14, 2026, with Paul acquiring 7,500 shares at $3.69 per share through a standard purchase. After this acquisition, Paul now owns 97,441 total shares of common stock, demonstrating substantial personal investment in the company.

Transaction Structure and Filing Information

The purchase was reported via a Form 4 SEC filing on May 14, 2026. Form 4 filings are required within two business days of insider transactions and provide transparency to the public. This particular filing shows a straightforward purchase transaction with no complex derivatives or options involved. The filing date matched the transaction date, indicating immediate disclosure compliance.

Ownership Position After Purchase

Following this acquisition, Bisaro Paul’s stake in Myriad Genetics increased significantly. His total holdings now stand at 97,441 shares of common stock. This substantial position demonstrates Paul’s long-term commitment to the company and his belief in its future prospects. Directors typically maintain meaningful equity stakes to align their interests with shareholders.

What This Insider Purchase Signals About MYGN

Insider buying often carries more weight than insider selling in market analysis. When company leaders purchase shares with personal funds, they’re betting on future performance. Bisaro Paul’s acquisition of 7,500 shares suggests confidence in Myriad Genetics’ strategic direction and market opportunities.

Confidence in Company Direction

Directors don’t typically purchase shares unless they believe the stock is undervalued or positioned for growth. Paul’s decision to invest approximately $27,637.50 at the current price point indicates positive sentiment about MYGN’s prospects. This type of insider activity often precedes positive announcements or reflects management’s assessment of the company’s competitive position in genomics and precision medicine.

Market Context and Timing

The timing of this purchase matters for investors analyzing insider sentiment. May 2026 represents a specific market moment for Myriad Genetics. By purchasing shares at this price, Paul is essentially voting with his wallet on the company’s valuation and future direction. Insider purchases during uncertain market conditions carry particular significance.

Understanding Form 4 Filings and Insider Trading Regulations

SEC Form 4 filings are the primary mechanism for tracking insider transactions. These documents provide critical transparency about executive and director trading activity. Understanding how to read these filings helps investors identify meaningful insider signals and distinguish between routine transactions and significant strategic moves.

Form 4 Filing Requirements and Disclosure Rules

Insiders must file Form 4 documents within two business days of any transaction. The form captures essential details including transaction date, number of shares, price per share, and resulting ownership position. These filings are public records available through the SEC’s EDGAR database. Myriad Genetics insiders are subject to these same disclosure requirements as all public company executives and directors.

Interpreting Transaction Codes and Ownership Data

Form 4 filings use standardized codes to classify transactions. Bisaro Paul’s transaction was coded as a “P-Purchase,” indicating a straightforward acquisition of common stock. The filing also shows his total securities owned after the transaction, providing context for the size of his stake. This transparency allows investors to assess whether insiders are accumulating or reducing their positions over time.

Myriad Genetics Stock Performance and Insider Perspective

Myriad Genetics operates in the genomics and precision medicine sector, a dynamic and growing industry. The company’s market capitalization stands at approximately $341.9 million, reflecting its position as a mid-cap healthcare player. Bisaro Paul’s purchase at $3.69 per share provides a data point for understanding current valuation levels and insider assessment of value.

MYGN’s Market Position and Growth Prospects

Myriad Genetics focuses on genetic testing and personalized medicine solutions. The company serves multiple markets including oncology, reproductive health, and psychiatric care. Director Paul’s confidence in acquiring additional shares suggests belief in the company’s ability to expand market share and drive revenue growth. Meyka AI rates MYGN a grade of B, reflecting solid fundamentals and sector positioning.

Insider Accumulation as a Bullish Signal

When directors accumulate shares rather than sell, it typically signals optimism about future performance. Paul’s decision to increase his stake from existing levels to 97,441 shares demonstrates conviction. This type of insider buying often attracts attention from value-focused investors who view executive purchases as validation of investment thesis.

Final Thoughts

Bisaro Paul’s purchase of 7,500 MYGN shares at $3.69 per share represents meaningful insider confidence in Myriad Genetics. The transaction, disclosed via SEC Form 4 filing on May 14, 2026, shows a director willing to invest personal capital in the company. With Paul now holding 97,441 total shares, his substantial stake aligns his interests with shareholders. This insider buying activity suggests positive sentiment about MYGN’s strategic direction and market opportunities in genomics and precision medicine. For investors monitoring insider activity, this purchase provides concrete evidence of executive confidence in the company’s future prospects.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.